lapatinib has been researched along with bilirubin in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (bilirubin) | Trials (bilirubin) | Recent Studies (post-2010) (bilirubin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 25,921 | 1,337 | 5,871 |
| Protein | Taxonomy | lapatinib (IC50) | bilirubin (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 3.3884 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.3183 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
1 other study(ies) available for lapatinib and bilirubin
| Article | Year |
|---|---|
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |